Digest Network Come funziona
Network
/
Società
Ar
Non verificato

Arrowhead Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaCardiologiaFarmaceuticaMedicina - VarieSalute

83 comunicati stampa

Guarda tutti i comunicati
02/06/2026
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
27/05/2026
Scienza
Salute
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Eventi
Industria
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
26/05/2026
Web e Social Network
Eventi
Industria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
07/05/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
05/05/2026
Industria
Cardiologia
Biotecnologia
Sanità
Salute
Farmaceutica
Scienza
Medicina - Varie
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/05/2026
Eventi
Cardiologia
Salute
Sanità
Comunicazione
Farmaceutica
Scienza
Biotecnologia
Medicina - Varie
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
01/05/2026
Industria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
24/04/2026
Industria
Scienza
Medicina - Varie
Cardiologia
Sanità
Salute
Farmaceutica
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
20/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
28/03/2026
Eventi
Industria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0